Dupilumab (RegN-668) can inhibit IL-4 and IL-13 signaling pathways and significantly improve moderate to severe atopic dermatitis.It is a human monoclonal antibody (IL-4r-inhibitor) that completely inhibits il-4 receptors.

Dupilumab suppressed mRNA expressions of genes related to activation of T cells, DCs, eosinophils, inflammatory pathways, and TH2-inducing chemokines in skin lesions. No significant reduction in IL-17A or IL-22 levels is detected, but large reductions in expression of IL-17–related genes, such as elafin (PI3), IL23p19/IL23A, and S100A8 and trends for suppression (CXCL1 and S100A7) are found with 300 mg of Dupilumab. Major suppressions of hyperplasia-related genes (eg, K16) and reductions in expression of S100A genes are evident with 300 mg of Dupilumab by using microarrays and qRT-PCR.

1190264-60-8

SAR-231893;REGN-668